netFormulary
 Report : A-Z NHS England items in Formulary 15/08/2020 02:42:52
[Back]
 
Section Status NHS England Name
20 Non Formulary MHS England 3, 4 Diaminopyridine 
08.01.05 Restricted Use MHS England Abemaciclib Verzenios®
11.99.99.99 Restricted Use MHS England Adalimumab Amgevita®, Humira®, Imraldi®
13.05.03 Restricted Use MHS England Adalimumab Amgevita®,Humira®, Imraldi®
08.01.05 Restricted Use MHS England Afatinib Giotrif®
10.01.03 Restricted Use MHS England Anakinra Kineret®
09.08.01 Restricted Use MHS England Asfotase alfa Strensiq®
10.02 Restricted Use MHS England Ataluren Translarna®
08.01.05 Restricted Use MHS England Atezolizumab Tecentriq®
10.04 Restricted Use MHS England Autologous chondrocyte implantation (ACI) 
08.01.05 Restricted Use MHS England Avelumab Bavencio®
05.01.09 Restricted Use MHS England Bedaquiline Sirturo®
03.04.02 Restricted Use MHS England Benralizumab Fasenra®
09.08.01 Formulary MHS England Betaine Cystadane®
05.03.01 Restricted Use MHS England Bictegravir, emtricitabine, tenofovir alafenamide  Biktarvy®
08.01.05 Restricted Use MHS England Binimetinib Mektovi®
08.02.03 Restricted Use MHS England Blinatumomab Blincyto®
08.01.05 Restricted Use MHS England Brigatinib Alunbrig®
08.01.05 Restricted Use MHS England Cabozantinib Cabometyx®
08.01.05 Restricted Use MHS England Carfilzomib Kyprolis®
08.01.05 Restricted Use MHS England Ceritinib Zykadia®
10.01.03 Restricted Use MHS England Certolizumab Pegol Cimzia®
09.08.01 Restricted Use MHS England Chenodeoxycholic acid 
08.01.03 Restricted Use MHS England Cladribine Mavenclad®
08.01.05 Restricted Use MHS England Crizotinib Xalkori®
05.03.03.02 Restricted Use MHS England Daclatasvir  Daklinza®
08.01.05 Restricted Use MHS England Daratumumab Darzalex®
05.03.03.02 Restricted Use MHS England Dasabuvir Exviera®
20 Non Formulary MHS England Dibotermin alfa (recombinant human (Bone Morphogenetic Protein-2; rhBMP-2)  InductOs® 1.5 mg/ml powder, solvent and matrix for implantation matrix
20 Restricted Use MHS England Dibotermin Alfa, rhBMP-2 (Bone morphogenetic protein-2 ) Inductos®
08.02.04 Formulary MHS England Dimethyl fumarate Tecfidera®
08.02.03 Restricted Use MHS England Durvalumab Imfinzi®
09.01.03 Restricted Use MHS England Eculizumab 
05.03.03.02 Restricted Use MHS England Elbasvir and Grazoprevir  Zepatier®
09.08.01 Restricted Use MHS England Eliglustat Cerdelga®
02.11 Restricted Use MHS England Emicizumab Hemlibra®
08.01.05 Restricted Use MHS England Encorafenib Braftovi®
13.05.03 Restricted Use MHS England Etanercept Enbrel®, Benepali®
06.06.01 Restricted Use MHS England Etelcalcetide Parsabiv®
08.01.05 Restricted Use MHS England Everolimus Votubia®
09.01.06 Formulary MHS England Filgrastim 
05.03.03.02 Restricted Use MHS England Glecaprevir and Pibrentasvir Maviret®
09.08.01 Restricted Use MHS England Glycerol Phenylbutyrate Ravicti®
11.08 Restricted Use MHS England Holoclar® 
08.01.05 Restricted Use MHS England Ibrutinib Imbruvica®
08.03.04.01 Restricted Use MHS England Intrabeam radiotherapy system Carl Zeiss UK
03.07 Restricted Use MHS England Ivacaftor 
08.01.05 Restricted Use MHS England Ixazomib Ninlaro®
03.04.03 Restricted Use MHS England Lanadelumab Takhzyro®
05.03.03.02 Restricted Use MHS England Ledipasvir and Sofosbuvir Harvoni®
09.01.06 Restricted Use MHS England Lenograstim Granocyte®
08.01.05 Restricted Use MHS England Lenvatinib Lenvima®
08.01.05 Restricted Use MHS England Lenvatinib Kisplyx®
09.08.01 Formulary MHS England Levocarnitine Carnitor®
08.01.05 Restricted Use MHS England Liposomal Cytarabine–Daunorubicin  Vyxeos®
03.07 Restricted Use MHS England Lumacaftor/ivacaftor Orkambi®
03.04.02 Restricted Use MHS England Mepolizumab Nucala®
09.08.01 Formulary MHS England Mercaptamine 
08.01.05 Restricted Use MHS England Midostaurin Rydapt®
08.01.05 Restricted Use MHS England Niraparib Zejula®
09.08.01 Formulary MHS England Nitisinone Orfadin®
08.02.04 Restricted Use MHS England Nivolumab Opdivo ®
01.09.01 Restricted Use MHS England Obeticholic acid Ocaliva®
08.02.04 Restricted Use MHS England Ocrelizumab Ocrevus®
08.03.04.03 Restricted Use MHS England Octreotide Sandostatin®
08.03.04.03 Restricted Use MHS England Octreotide Sandostatin Lar®
05.03.03.02 Restricted Use MHS England Ombitasvir, Paritaprevir and Ritonavir Viekirax®
08.01.05 Restricted Use MHS England Paclitaxel 
08.01.05 Restricted Use MHS England Palbociclib Ibrance®
09.01.06 Restricted Use MHS England Pegfilgrastim Neulasta®
08.01.05 Restricted Use MHS England Pembrolizumab Keytruda®
09.01.07 Restricted Use MHS England Plerixafor Mozobil®
08.01.05 Restricted Use MHS England Ribociclib Kisqali®
03.03.03 Restricted Use MHS England Roflumilast Daxas®
09.08.01 Formulary MHS England Sodium Phenylbutyrate 
08.01.05 Restricted Use MHS England Streptozocin Zanosar®
03.07 Restricted Use MHS England Tezacaftor/Ivacaftor Symkevi®
08.01.05 Restricted Use MHS England Tisagenlecleucel  Kymriah®
10.01.03 Restricted Use MHS England Tocilizumab RoActemra®
20.01 Restricted Use MHS England Tocilizumab 
06.05.02 Restricted Use MHS England Tolvaptan Samsca®
08.01.05 Restricted Use MHS England Trastuzumab emtansine Kadcyla®
Cambridgeshire and Peterborough